Your Yourlocation: Home > Novartis and Boehringer competition in tiotropium bromide(136310-93-5) market

Both rival Novartis and Boehringer Ingelheim's combination of chronic obstructive pulmonary disease (COPD) treatment drugs have received positive results, which will occupy the dominant market of GlaxoSmithKline, the market valuation may reach 2018 14 billion.

Boehringer said the use of a fixed dose of LAMA tiotropium bromide(136310-93-5) and LABA olodaterol in a phase III trial could improve lung function in patients with chronic obstructive pulmonary disease longer than placebo and each drug itself.

Novartis reported that Ultibro, which is marketed in Europe, is also a LABA - LAMA combination that selected 900 patients for the combination of tiotropium bromide(136310-93-5) and formoterol.

Boehringer has not submitted any country to the approval of bronchodilator drug brand, Novartis is also in full swing to prepare for the FDA to review its treatment of drugs. GlaxoSmithKline is the only competitor to the LABA - LAMA combination in the US market, which last year received FDA approval from Anoro Ellipta, an EU - approved inhaler from the British drugmaker.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved